[go: up one dir, main page]

WO2008037037A3 - Médicament anti-asthmatique - Google Patents

Médicament anti-asthmatique Download PDF

Info

Publication number
WO2008037037A3
WO2008037037A3 PCT/BG2007/000021 BG2007000021W WO2008037037A3 WO 2008037037 A3 WO2008037037 A3 WO 2008037037A3 BG 2007000021 W BG2007000021 W BG 2007000021W WO 2008037037 A3 WO2008037037 A3 WO 2008037037A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthmatic
medicine
hydrochloricum
sulfuricum
sulfaguajacolicum
Prior art date
Application number
PCT/BG2007/000021
Other languages
English (en)
Other versions
WO2008037037A2 (fr
Inventor
Ivan Hristov
Original Assignee
Ivan Hristov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivan Hristov filed Critical Ivan Hristov
Publication of WO2008037037A2 publication Critical patent/WO2008037037A2/fr
Publication of WO2008037037A3 publication Critical patent/WO2008037037A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un médicament anti-asthmatique qui peut être utilisé en médecine humaine pour traiter un asthme ou une bronchite asthmatique. Ce médicament contient coffeinum purum, ergotamintartarat, zincum sulfuricum, papaverinum hydrochloricum, atropinum sulfuricum, aminophyllinum, glaucinum hydrochloricum, kalium sulfaguajacolicum et chlorpyraminum, dans les proportions suivantes [en mg] : coffeinum purum 30,00 à 250,00; ergotamintartarat 0,25 à 2,00; zincum sulfuricum 10,00 à 400,00; papaverinum hydrochloricum 30,00 à 200,00; atropinum sulfuricum 0,25 à 1,00; aminophyllinum 40,00 à 250,00; glaucinum hydrochloricum 30,00 à 250,00; kalium sulfaguajacolicum 100,00 à 600,00; chlorpyraminum 30,00 à 200,00. Ce médicament est avantageux en ce qu'il permet de maîtriser les crises d'asthme les plus aigües en l'espace de 30-40 minutes, en ce qu'il empêche la réapparition d'une respiration asthmatique douloureuse et de crises asthmatiques résultantes sur une période de 10 à 20 ans, voire au-delà, c'est-à-dire que la maladie est traitée en pratique, en ce qu'il empêche les effets secondaires importants et les complications causés par les corticostéroïdes et en ce qu'il est très bien supporté et n'engendre pas de complications.
PCT/BG2007/000021 2006-09-26 2007-09-19 Médicament anti-asthmatique WO2008037037A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG109687 2006-09-26
BG109687A BG109687A (bg) 2006-09-26 2006-09-26 Антиастматично лекарствено средство

Publications (2)

Publication Number Publication Date
WO2008037037A2 WO2008037037A2 (fr) 2008-04-03
WO2008037037A3 true WO2008037037A3 (fr) 2008-07-10

Family

ID=39060181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BG2007/000021 WO2008037037A2 (fr) 2006-09-26 2007-09-19 Médicament anti-asthmatique

Country Status (2)

Country Link
BG (1) BG109687A (fr)
WO (1) WO2008037037A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113633710A (zh) * 2021-09-29 2021-11-12 浙江养和健康管理科技有限公司 一种治疗支气管炎、哮喘和肺气肿的中药组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031222A1 (fr) * 1994-03-23 1996-10-10 Ivan Dimitrov Hristov Preparation antiashtmatique
US20010010825A1 (en) * 1998-07-28 2001-08-02 Toshihiro Shimizu Rapidly disintegrable solid preparation
BG105687U (en) * 2001-07-10 2003-01-31 "Софарма" Ад Combined means for affecting the respiratory system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031222A1 (fr) * 1994-03-23 1996-10-10 Ivan Dimitrov Hristov Preparation antiashtmatique
US20010010825A1 (en) * 1998-07-28 2001-08-02 Toshihiro Shimizu Rapidly disintegrable solid preparation
BG105687U (en) * 2001-07-10 2003-01-31 "Софарма" Ад Combined means for affecting the respiratory system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002478408 *
SZEMERE P A ET AL: "Consumption of antihistamines and antiasthmatics in Hungary during 1992-1996", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 118, no. 2-4, February 1999 (1999-02-01), pages 335 - 337, XP009096574, ISSN: 1018-2438 *
WAN HUAN-YING ET AL: "Effect of theophylline and glucose injection in treating acute asthma", ZHONGGUO XINYAO YU LINCHUANG ZAZHI, vol. 23, no. 3, March 2004 (2004-03-01), pages 159 - 163, XP002470608, ISSN: 1007-7669 *

Also Published As

Publication number Publication date
WO2008037037A2 (fr) 2008-04-03
BG109687A (bg) 2008-03-31

Similar Documents

Publication Publication Date Title
WO2005099715A3 (fr) Traitement de pathologies ophtalmiques
AU6918700A (en) Pharmaceutical compositions and methods for reducing the appearance of cellulite
WO2007133816A3 (fr) PROCÉDÉS DE TRAITEMENT DE LA DOULEUR ET DE L'INFLAMMATION DANS LE TISSU NEURONAL METTANT EN OEUVRE DES ANTAGONISTES IL-31Ra ET OSMRb
CN102002767A (zh) 具有护肤保健功能的珍珠中药纤维及其制备方法
WO2009079451A3 (fr) Compositions et procédés pour favoriser la guérison d'une plaie
EP2759302A3 (fr) 4F-benzoyl-TN14003 combiné avec rituximab pour une utilisation dans le traitement d'une tumeure
WO2009065093A3 (fr) Utilisation de cellules souches pour la cicatrisation de plaie
CN101926393A (zh) 一种冬虫夏草保健食用油
CN101427844A (zh) 无花果保健香烟
CN101584651A (zh) 一种珍珠护肤品
WO2008037037A3 (fr) Médicament anti-asthmatique
CN102793438A (zh) 抗菌蚕丝枕
CN102755507B (zh) 一种治疗风燥伤肺型急性支气管炎的中药汤剂
CN102210827B (zh) 用于戒烟的中药
KR20130142326A (ko) 발모 촉진제 조성물
CN101185722B (zh) 一种治疗脚气的浸剂药物
CN202197887U (zh) 一种防治冻疮手套
CN207785521U (zh) 一种治疗口疮的中药保健贴
CN1977820A (zh) 一种丝瓜美容品
CN104005254A (zh) 一种具有清热解酒功能的水松纸原纸及其制备方法
CN102370665A (zh) 治疗儿童盗汗的中药组合物及方法
CN101455685A (zh) 一种治疗小儿虚汗症的脐贴剂
CN101062090A (zh) 缓解癌症患者疼痛制剂的制备方法
CN2796427Y (zh) 足跟皲裂防治套
CN1243729A (zh) 一种治疗鸡眼的药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07815698

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07815698

Country of ref document: EP

Kind code of ref document: A2